TRACON Pharmaceuticals, Inc.(NASDAQ : TCON)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||2.85%||10.82||0.7%||$756.36m|
|VRTX||Vertex Pharmaceuticals, Inc.||-1.90%||197.76||1.9%||$406.87m|
|GILD||Gilead Sciences, Inc.||-0.10%||68.23||1.0%||$400.95m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.33%||576.52||2.7%||$355.06m|
|NTLA||Intellia Therapeutics, Inc.||-2.55%||138.24||2.3%||$257.18m|
|CRSP||CRISPR Therapeutics AG||1.61%||122.97||0.6%||$147.06m|
|EXAS||EXACT Sciences Corp.||1.36%||109.31||18.1%||$125.27m|
|XBIO||Xenetic Biosciences, Inc.||22.36%||4.98||0.0%||$125.03m|
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.